Log in with your email address username.


[Correspondence] Drug prices threaten the NHS

The recent Lancet Editorial1 (Aug 13, p 634) on the High Court ruling that rejected NHS England’s decision not to provide HIV pre-exposure prophylaxis (PrEP) reflected upon the difficult choices facing policy makers forced to choose between effectiveness and affordability in health interventions.